Challenges in Immuno-oncology (I-O): Future Use, Trial Design and Combination Strategies
Immuno-oncology (I-O) is the treatment of cancer with immunotherapy, by using therapies to stimulate or suppress the body’s own immune system to fight cancer. Several distinct modalities of immunotherapy exist, including cytokines, vaccines, viruses, adoptive cell transfer, and checkpoint blockade using monoclonal antibodies.
This report provides an assessment of the current status and future challenges of immuno-oncology across many indications. Overall, GlobalData expects innovative trial design and new combination drug approvals to drive immuno-oncology market growth.
This report combines primary research with a cross-specialty I-O KOL panel with in-house analyst expertise to provide an assessment of the marketplace. Components of the slide deck include -
Reasons to buy
- Primary research with 20 US- and EU-based KOLs, from eight cancer specialties - breast, gastrointestinal, genitourinary, head & neck, lung, melanoma, sarcoma and hematology
- Charts summarizing KOL’s opinions and identifying response patterns
- Call-outs of key information and details
- KOL quotes
- Insight from GlobalData’s specialist oncology analysts
- Develop and design your in-licensing and out-licensing strategies through a review of the potential of novel agents across tumor specialties by mechanism of action.
- Develop business strategies by understanding the trends shaping and driving the global immuno-oncology market.
- Drive revenues by understanding the key trends, innovative strategies and trial designs likely to impact the global immuno-oncology market in the future.
- Organize your sales and marketing efforts by understanding the immunotherapy combination approaches across indications that present maximum opportunities for consolidations, investments, and strategic partnerships.
- 1. Introduction
- 1.1 Related Reports
- 1.2 Upcoming Related Reports
- 2. Executive Summary
- 2.1 KOL Insight
- 2.2 GlobalData Insight
- 3. Research Panel Composition
- 3.1 5EU
- 3.2 US
- 4. Results and Implications
- 4.1 Future Use of Immunotherapy
- 4.1.1 Patterns in Unmet Needs
- 4.1.2 Clinical Potential of I-O in Oncology
- 4.1.3 Optimal Place for I-O in Treatment Algorithms
- 4.2 Challenges in I-O Trial Design
- 4.2.1 Predictive Biomarkers
- 4.2.2 Clinically Relevant Endpoints
- 4.2.3 Study Recruitment
- 4.2.4 Single-Arm Studies for Regulatory Approval
- 4.3 I-O Approaches and Combination Strategies
- 4.3.1 Potential of I-O Combinations
- 4.3.2 Potential of Novel Agents by Mechanism of Action
- 5. Appendix
- 5.1 Methodology
- 5.2 About the Authors
- 5.3 About GlobalData
- 5.4 Contact Us
- 5.5 Disclaimer